Commentary to a paper by Flosadóttir & Bjarnason on full dapsone dose made possible by control of anaemia with darbepoetin-alpha.
Mobacken
Håkan
H
Department of Dermatology, Groupe hospitalo-universitaire Caremeau, CHU Nîmes, Place du Professeur Robert Debré, France.
D000369:Aged, 80 and over; D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000517:prevention & control*; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male
D006397:Hematinics; D007166:Immunosuppressive Agents; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D003622:Dapsone